Evidence map›Paper›PMID 32086571›Full record

ArticleWorld journal of urology2020

Super early detailed assessment of lower urinary tract symptoms after holmium laser enucleation of the prostate (HoLEP): a prospective study.

Sascha A Ahyai, Irina Marik, Tim A Ludwig, Andreas Becker, Saman Asdjodi, Luis Kluth, Felix Chun, Margit Fisch, Marianne Schmid

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05393921 (The Clinical Efficacy of Intravesical Botox Injections When Combined With HoLEP Surgery in Patients With Benign Prostatic Hyperplasia and Overactive Bladder), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05393921 phase4withdrawnnot on this mapstarted 2026, after this paper: background citation

The Clinical Efficacy of Intravesical Botox Injections When Combined With HoLEP Surgery in Patients With Benign Prostatic Hyperplasia and Overactive Bladder

TypeinterventionalSponsorUniversity Hospitals Cleveland Medical CenterRan2026 to 2027Enrolled0ConditionsBenign Prostatic Hyperplasia, Overactive BladderArmsIntravesical Botox injection
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sascha A Ahyai *Department of Urology, University Medical Center Goettingen, Robert-Koch-St. 40, 37075, Goettingen, Germany. sascha.ahyai@med.uni-goettingen.de.
Irina Marik *Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Tim A LudwigDepartment of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andreas BeckerDepartment of Urology, University Medical Center Frankfurt a.M., Frankfurt a. M, Germany.
Saman AsdjodiDepartment of Urology, University Medical Center Goettingen, Robert-Koch-St. 40, 37075, Goettingen, Germany.
Luis KluthDepartment of Urology, University Medical Center Frankfurt a.M., Frankfurt a. M, Germany.
Felix ChunDepartment of Urology, University Medical Center Frankfurt a.M., Frankfurt a. M, Germany.
Margit FischDepartment of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Marianne SchmidDepartment of Urology, University Medical Center Goettingen, Robert-Koch-St. 40, 37075, Goettingen, Germany.ORCID http://orcid.org/0000-0002-6796-431X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo prospectively investigate early and consecutive changes of lower urinary tract symptoms (LUTS), specifically storage symptoms after holmium laser enucleation of the prostate (HoLEP).

methodsPatients referred for HoLEP completed the International Prostatic Symptom Score (IPSS) the day before, at discharge, and 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, and 52 weeks after HoLEP. Total IPSS was stratified into mild (score 0-7), moderate (8-19), and severe (20-35) LUTS. Storage symptoms were sub-stratified into storage "negative" and "positive". IPSS changes served as the main postoperative outcome. Mixed linear models identified risk factors affecting postoperative recovery of LUTS.

resultsBetween December 2010 and 2012, 144 consecutive HoLEP patients were prospectively included in the study. Preoperatively 57.6% of the cohort reported severe storage symptoms (mean total IPSS: 22.6 ± 5.0). Total IPSS decreased significantly immediately after surgery (p < 0.001). Patients with severe LUTS, storage-positive sub-score, and high maximum urinary flow rate were affected by a rebound of mainly storage symptoms 6-8 weeks after HoLEP and prolonged recovery from LUTS. Of these, about 7.4% presented persisting urge complaints. Finally, 12 weeks following HoLEP, the vast majority of patients were symptom-free. Limitations of this study include missing urodynamic workup and a comparative patient cohort.

conclusionImmediately after HoLEP, patients experience a significant decrease of LUTS. Continuous symptom recovery seems to be hampered in patients with severe and storage-positive baseline symptoms. (De-novo) storage symptoms slightly affect postoperative recovery. Quality of life is restored to a stable and significantly improved status 3 months after surgery.

Indexed as

AgedHumansLasers, Solid-StateLower Urinary Tract SymptomsMaleMiddle AgedProspective StudiesProstatectomyProstatic HyperplasiaSymptom AssessmentTime FactorsBenign prostate enlargementHolmium laser enucleation of the prostateLower urinary tract symptomsQuality of lifeStorage symptoms

Identifiers

PMID32086571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.